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Introduction
Amphetamines, or ‘amphetamine-related 
drugs’, are stimulants prescribed for a variety 
of conditions (e.g. attention deficit hyperactivity 
disorder (ADHD) and the sleep disorder 
narcolepsy) with the temporary action of 
increasing the activity of the central nervous 
system, producing effects similar to adrenaline. 
Although some amphetamines such as Adderall 
and Dexedrine are prescribed, this paper will 
explore the harms associated with the illicit 
use of certain amphetamines. Despite heavy 
media coverage regarding amphetamines 
and increased research attention in some 
countries, the harm reduction response remains 
underdeveloped when compared to the response 
to opiates and injecting-related harms. The 
overwhelming majority of academic literature 
focuses on the harms related to amphetamine 
use, rather than harm reduction. Recently, 
it has been demonstrated that some of the 
harms associated with amphetamine use have 
been greatly exaggerated.(1) Harm reduction 
programmes do exist and new guidance has 
been compiled, but there is an urgent need for 
harm reduction-focused research, evaluation 
of current programmes, further documentation 
of experiences, and expansion of effective 
interventions. This paper will discuss the 
emerging responses to amphetamine-related 
harms and consider the next steps for the 
international harm reduction community. 
Definitions and effects
Amphetamine, methamphetamine, 
methcathinone and cathinone, the four drugs 
discussed in this paper, stimulate the central 
nervous system and cause the rapid release 
of monoamine neurotransmitters.(2,3) They 
can produce feelings of energy, confidence, 
alertness, well-being, talkativeness and 
increased sex drive. They increase blood 
pressure, heart rate and other metabolic 
functions, and decrease appetite.(1,4,5) 
Cathinone is the active substance in fresh khat, 
a North African shrub whose leaves have been 
chewed for centuries for their mild stimulant 
effect. The differences between cathinone and 
methcathinone are similar to those between 
amphetamine and methamphetamine: 
methcathinone is stronger than cathinone and 
produces similar but more intense effects, 
including a sense of invincibility, energy 
and increased sex drive, and talkativeness. 
Euphoric effects are often more pronounced 
than with amphetamine or methamphetamine, 
leading some to compare cathinone and 
methcathinone to cocaine. Negative effects are 
similar to those caused by amphetamine and 
methamphetamine.(6) 
Although amphetamines are often grouped 
with ecstasy in the category ‘amphetamine-
type stimulants’, this paper will limit its scope 
to amphetamine, methamphetamine, cathinone 
and methcathinone. The paper will exclude 
ecstasy primarily because of the dramatic 
differences in patterns of ecstasy use. People 
who use ecstasy are less likely to become 
dependent on it and are much less likely to inject 
or smoke it, reducing the frequency of harms 
associated with these routes of administration.
For simplicity, the plural ‘amphetamines’ will be 
used to refer to the four amphetamine-like drugs 
discussed here. Individual drug names (e.g. the 
singular ‘amphetamine’) will be used to discuss 
issues specific to one drug or when the research 
discussed refers to one drug rather than to the 
group.
Overview of amphetamine use around the world
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It is estimated that there are between 13.9 and 
54.8 million people who use amphetamines 
worldwide,(7) with 12 million thought to be 
residing in the European Union.(8) The wide-
ranging global figures reflect the current dearth 
of accurate data on the topic. Data collection 
methods often vary dramatically from country to 
country, and some countries do not collect or 
analyse data at all, meaning that international, 
large-scale epidemiological information 
related to amphetamine use is extremely 
limited. Where information is available, we 
have seen a marked increase in amphetamine 
use in South Africa,(9,10) with the percentage 
of patients in a drug treatment centre in Cape 
Town reporting methamphetamine as their 
primary or secondary drug rising from 0.7% 
in 2002 to 47% in 2009.(9) Methamphetamine 
use has also steadily increased in the United 
States, with an estimated 595,000 people 
using methamphetamine in the past month,(11) 
and has been reported in Brazil, predominantly 
among truck drivers.(12,13) In Western Europe, 
although amphetamine use has been reported 
by only 2.5% of the population,(14) the injecting 
of stimulants has posed challenges for needle 
and syringe programmes (NSPs) since more 
frequent injection requires more syringes, and 
adapted outreach is required to enable people 
who use stimulants to access these services.(15)
Reports from the Czech Republic and 
Slovakia indicate a rise in the number of 
people entering treatment centres reporting 
problem pervitin use (a form of crystalline 
methamphetamine).(14) In Hungary it is thought 
that every second person who injects drugs is 
now using a new psychoactive substance (NPS), 
with 48% reporting the sharing of needles. In 
much of Asia, demand for drug treatment related 
to methamphetamine use remains high,(16,17) 
with 74% of people who use drugs receiving 
treatment for crystalline methamphetamine 
(crystal meth) in Cambodia,(18) and 50.8% in 
one treatment centre in Laos PDR receiving 
treatment for methamphetamine use.(16) 
However, the majority of treatment facilities in 
Asia still do not provide amphetamine-specific 
treatment services.
Civil society organisations have also noted a 
recent increase in the use of amphetamines 
in both Australia and New Zealand.(19,20) In a 
study looking at 15 years of HIV surveillance 
in Australia, 31% of people who inject drugs 
had recently injected methamphetamine 
(n=22,478),(21) with another study between 
2008 and 2013 finding a similar increase in 
methamphetamine injecting.(22) It is argued 
that New Zealand has seen a decrease in 
amphetamine use from 2.2% in 2009 to 1% in 
2013.(23) However, experts believe these figures 
to be inaccurate due to both altered survey 
methodology on behalf of the ministry of health, 
and the availability and ease of supply.(23) 
In response to the increased use of 
amphetamines, the United Nations Office on 
Drugs and Crime (UNODC) started the SMART 
Programme, which sought to generate, manage, 
analyse and report synthetic drug information, 
with East Asia being its first area of priority.(24) 
The results of this are yet to be published.
Forms and routes of administration 
Amphetamines are produced in pill, powder, 
crystalline and liquid forms. They can be 
swallowed, snorted, smoked, injected or 
inserted anally. The crystalline form (often called 
crystal meth, ice or glass) is most often smoked. 
It is usually more pure than other forms since 
it is difficult to produce crystals with impure 
materials.(25)
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Harms related to the use of amphetamines
Much of the harms related to amphetamine 
use refers to heavy rather than recreational 
use, and as noted previously, can often appear 
disproportionately represented in the literature. 
Injecting
The risks associated with injecting 
amphetamines are largely the same as those 
of opiate injecting, including HIV, hepatitis, 
endocarditis, abscesses, sepsis and collapsed 
veins. Although harm reduction services for 
people who inject amphetamines are far fewer 
than for people who use opiates, in countries 
where prevalence of amphetamine injecting is 
high and harm reduction services are already 
well established, innovative approaches for 
this sub-group are in place. For example, in the 
Czech Republic, where amphetamine injecting 
accounts for approximately two-thirds of all 
injecting drug use,(26) harm reduction facilities are 
being encouraged to distribute empty gelatine 
capsules to promote the swallowing rather 
than injecting of amphetamines.(27) Although the 
approach has not yet been evaluated properly, 
early assessment has indicated its benefits as a 
harm reduction intervention, including simplicity, 
safety and low cost, with drug users reporting 
the onset of effects as comparable to that of 
injecting. There are, however, limitations such 
as gastric ulcers associated with long-term 
oral use, nausea and emesis. Therefore, as an 
approach this should be investigated further. 
Smoking and snorting
Heavy users of amphetamines are more likely 
to smoke than inject, especially if they are 
using crystal meth. The dehydration caused by 
amphetamine use can cause the lips to crack 
and bleed, making people more likely to contract 
and transmit infections via shared smoking 
paraphernalia. Smoking on foil or in a pipe can 
cause burns to the fingers and face, and using 
contaminated containers (e.g. paint cans) or 
inappropriate materials (e.g. plastic containers) 
can lead to inhalation of toxic fumes.(28) Straws 
used for snorting amphetamines can become 
contaminated with blood and thus transmit 
blood-borne viruses, notably hepatitis C.(29)
Side effects
Although many of the side effects of 
amphetamine use are rare, or only found among 
people who regularly use high doses, they 
may include anxiety, insomnia, aggression,(30) 
chest pain, hypertension, tachycardia and 
other cardiac arrhythmias.(31) High doses, 
particularly in the context of repeated binges, 
can cause temporary psychosis that includes 
mood swings, visual, auditory and sensory 
hallucination, paranoia, delusion, obsessive 
thought patterns, impulsivity and the potential 
for aggression.(32)
Amphetamines and sexual activity
Much of the discussion of amphetamines-
related harm has focused on sexual risk-
taking associated with methamphetamine use, 
especially among men who have sex with men 
(MSM). In a study undertaken in Canada between 
2005 and 2008, unprotected sex was more 
common among gay, bisexual or transgender 
populations using methamphetamines.(33) A 
link was also observed between increased 
vulnerability (e.g. homelessness, warrants and/
or area restrictions) and sexual risk-taking 
associated with amphetamine use, highlighting 
the ways in which drug laws and policies 
may worsen the health of vulnerable groups, 
putting them at greater risk of HIV.(34) The 
study also found an associated link between 
unprotected sex among female sex workers 
and methamphetamine use,(33) which can also 
be linked to structural vulnerabilities such 
as client pressure to engage in unsafe sex 
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practices.(35) The 2015 European drug report 
from the European Monitoring Centre for Drugs 
and Drug Addiction (EMCDDA) also notes 
concern regarding the spread of stimulant 
injecting among men who have sex with men, 
particularly in large European cities which are 
seeing an increase in ‘chem-sex’ parties, having 
implications for HIV transmission via risk-taking 
sexual practices.(8) However, a study conducted 
in London found that although engaging in 
‘chem-sex’ unwittingly led some men to greater 
sexual risk-taking, others maintained strict rules 
regarding safer sex.(36) Therefore, establishing a 
direct link between use of methamphetamines 
and sexual risk among this population remains 
ambiguous. There are online resources available, 
primarily for men who have sex with men, giving 
a variety of harm reduction approaches and 
ways to stay safe when using amphetamines.(37)
Although some have documented increased 
sexual risk behaviour among people who use 
amphetamines, it is difficult to untangle the 
relationship between amphetamines and sex.
(38) Many people use the disinhibiting effects 
of amphetamines to facilitate sex, including 
high-risk sex, with the impulsivity produced by 
amphetamines making people potentially more 
likely to forgo condoms.
Risk for people living with HIV
There is reason to believe that amphetamines 
can increase the likelihood of HIV infection 
during sex: they dry mucous membranes, 
decrease sensitivity of the genital and rectal 
areas, and delay orgasm, increasing the risk 
of torn membranes vulnerable to infection.(38) 
Research also suggests that amphetamine use 
by people living with HIV is associated with 
increases in viral replication and viral load, even 
among people receiving antiretroviral therapy 
(ART).(39) However, this is believed to be due 
to the likelihood of regular methamphetamine 
users not adhering fully to ART treatment.
HIV combined with methamphetamine use 
is also thought to contribute to neuronal cell 
injury and death. However, understanding the 
specific relationship between the two would 
require further study.(40) Amphetamines may 
also negatively affect HIV-related dementia.(38) 
Frequent use of amphetamines has been inked 
to increased risk of lymphoma in people living 
with HIV.(41) 
Amphetamines and pregnancy
The use of amphetamines during pregnancy 
does not appear to cause congenital defects. It 
has been associated with elevated risks of heart 
defects,(42) and cleft lip and palate(43) in studies 
in which the subjects used multiple drugs, 
confounding results. Use of amphetamines 
in pregnancy has also been correlated with 
low birth weight, premature birth, post-
partum haemorrhage and retained placenta.
(44) In more recent studies, prenatal exposure 
to amphetamines has been associated with 
increased emotional reactivity and anxiety in 
children between the ages of three and five,(45) 
and subtle deficits in inhibitory control during 
early school years.(46)
As with better-studied drugs such as cocaine 
and heroin, it is important to remember the 
complex set of factors that affect the course of 
pregnancy, and to be wary of giving too much 
weight to the drug itself for negative outcomes. 
For example, poor nutrition, irregular sleep 
patterns, tobacco use, alcohol use and lack of 
access to prenatal care have a greater effect on 
pregnancy outcome than cocaine use in itself.
(47) Heavy use of amphetamines often leads to 
poor nutrition, lack of sleep, increased tobacco 
use and difficulty planning ahead and keeping 
appointments, meaning that pregnant women 
who use amphetamines are at risk for many 
of the factors that contribute to a high-risk 
pregnancy. Harm reduction measures to deal 
with this set of risks, along with drug treatment, 
9
are likely to be effective in improving pregnancy 
outcomes. 
Production and environmental harms
Illicit synthesis of amphetamines can be 
dangerous both for people making or ‘cooking’ 
the drug and those around them. Chemical 
processes involved in the production of 
amphetamines require and produce flammable, 
carcinogenic, poisonous and caustic 
substances.(48) Some of these can cause 
explosions if managed improperly. These risks 
are greater if cooks have poor knowledge 
of chemical processes or if their judgement 
is impaired by drug use or other factors. 
Chemicals can spread into surrounding areas 
and contaminate soil and water. Proper clean-
up of methamphetamine labs is expensive, 
time-consuming and at times dangerous.(6)
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Harm reduction for people who use amphetamines
Harm reduction for people who use 
amphetamines follows the same fundamental 
principles as harm reduction for people who use 
opiates:
 > Meet people who use amphetamines 
‘where they are’.
 > Give people who use amphetamines 
information, means and opportunities 
for behaviour change to improve their 
health.
 > Organise amphetamine harm reduction 
programmes around their needs rather 
than imposing external demands.
 > Provide safer injecting supplies and 
accurate information.
 > Provide mobile services and outreach 
workers to access people who use 
amphetamines unwilling or unable to 
come to a harm reduction site.
 > Engage people who actively use, 
or who have previously used, 
amphetamines as staff members, 
volunteers and advisors.
 > Refer and assist in accessing other 
needed services, such as cognitive 
behavioural therapy (CBT) and 
motivational interviewing.
Some harm reduction programmes, designed 
for and accustomed to working with people 
who use opiates, can be daunted by the idea 
of working with people who use amphetamines, 
as there are differences in basic needs. For 
example, in many settings people are more 
likely to smoke amphetamines than opiates, 
and the psychological problems associated 
with heavy use can make them seem more 
‘difficult’ as clients than people who use 
opiates. Use of amphetamines, as noted 
earlier, can lead to anxiety, insomnia and 
aggression,(30) mood swings, visual, auditory 
and sensory hallucinations, paranoia, delusions, 
obsessive thought patterns and impulsivity,(32) 
all of which can make counselling and service 
provision a challenge. Finally, there is little solid 
evidence relating to pharmacological treatment 
for amphetamine dependence. This can be 
disconcerting to providers accustomed to being 
able to offer treatments as straightforward and 
effective as methadone and buprenorphine.
Thankfully, experience from various countries 
has shown that harm reduction programmes can 
respond effectively to the harms associated with 
the use of amphetamines. Table 1, developed 
using several existing resources,(27,28,37,38,53-56) 
Innovative programmes for stimulants: lessons from Latin America
Research is increasing into the harms related to non-injecting drug use in Latin America, 
with snorting and smoking of cocaine and its derivatives acknowledged as the most 
predominant form.(49,50) Growing recognition of HIV prevalence and hepatitis C among 
people who use cocaine has increased the harm reduction response in this region. 
For example, in Brazil the non-governmental organisation É de Lei of São Paulo has 
successfully distributed new crack pipes(51) in an attempt to reduce viral hepatitis 
transmission through the sharing of pipes. In São Paulo, the Bracos Abertos (Open Arms) 
programme offers healthcare, information on treatment, paid work and three meals a day 
to people in the favelas who use crack cocaine. The programme has already made a 
significant impact on health outcomes, as well as on lowering the levels of stigma and 
discrimination associated with drug use in the area.(52)
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presents key aspects of harm reduction interventions for people who use amphetamines. These 
approaches are useful not only for harm reduction service providers, but also for people who use 
amphetamines, their friends and family, primary and emergency healthcare providers, and law 
enforcement personnel in contact with people who use amphetamines. There may be a role for 
harm reduction service providers in training others to respond appropriately to amphetamine-
related harms.




 » Diminishing 
food intake
 » Eating only 
junk food
 » Not sleeping
 » Malnutrition and 
dehydration
 » Increased risk of 
anxiety, paranoia 
and psychosis
 » Decreased high; 
need for higher 
dose to achieve 
same effects
 » Intensified ‘crash’ 
 » Provide water, juice and healthy food where possible, 
especially for people who are homeless, marginally 
housed and/or impoverished 
 » Stress the need to sleep or at least rest in a darkened 
room, eat healthy food (particularly fruits and vegetables) 
and drink water regularly. Point out that these are not 
abstract health concerns, but have immediate positive 
effects on the experience of day-to-day use




 » Eating sugary 
foods
 » Grinding teeth




 » Dental problems
 » Stress the importance of hydration and dental hygiene




 » Binges (heavy 
use over a 
period of days 
or weeks)





and other health 
problems
 » Encourage people to plan for breaks in advance. Develop 
methods to help them keep track of how long and how 
much they have been using, take a break at the limit 
they have set for themselves, eat well before using 
and stay hydrated while using. When introducing and 
implementing these plans, it can be helpful to have a 
‘harm-reduction buddy’ – someone they trust who can 
support their efforts
 » Heavy use  » Withdrawal and crashes
 » Stress that depression, fatigue, moodiness and aches are 
a natural part of withdrawal and will pass with time
 » Inform people that focusing on pleasant and distracting 
activities, keeping close to supportive people, and 
maintaining a healthy diet and routine will help them to 
manage withdrawal and crashes
 » Once the crash has receded, help people to develop their 
own strategies to reduce crashes, using the same tactics 
effective for episodes of paranoia and psychosis 
 » Once the crash has receded, explore referral to CBT or 
psychological support mechanisms
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Area Behaviour Harm Harm Reduction Strategy
Reducing 
harm related 
to modes of 
use
 » Sharing 
injecting 
equipment




 » Smoking with 
toxic materials
 » Using pipes 
that can easily 
cause burns
 » Risk of blood-
borne diseases, 
lung damage, 
toxicity, cuts and 
burns
 » Distribute sterile injecting equipment and information on 
safer injecting
 » Distribute glass stems with gauze or individual pipe tips
 » Teach people how to make safer pipes 
 » Distribute lip balm and burn salve
 » Distribute empty gelatine capsules for people to fill with 
amphetamines as an alternative to injecting
 » Transition to 
smoking and 




 » Dependence 
develops more 
quickly and is 
more severe 
among people 
who inject and 
who use more 
potent forms
 » Increased risk 
of blood-borne 
viruses
 » Inform people who swallow or snort about the risks of 
injecting and smoking, and about safer injecting and 
smoking techniques
 » Encourage people not to transition to a more intense 
route
 » Give people who inject or smoke appropriate information 
about safer methods and encourage them to transition to 
snorting or swallowing if possible
 » Inform people that smoking from a pipe produces a faster 
and more intense high than smoking on foil and inhaling 
smoke through a tube or smoking from a joint, and that 
switching to one of these methods is another harm 
reduction strategy
 » Injecting many 
times in one 
sitting
 » Increased risk of 






 » Use a butterfly needle scheme, eliminating the need 
to enter the vein repeatedly and repeat the risk of 
associated harms noted above. Distribute appropriate 





 » Picking at 
‘speed bugs’
 » Open wounds 
that can become 
infected
 » Use methods described above to deal with delusions
 » It may be helpful to create non-invasive ‘treatment’ for 
the bugs to calm the person during acute episodes
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 » Risk of harm to 
self or others
 » Be calm and reassuring
 » Take the person to a quiet, calming place and try to turn 
their attention to something else
 » Take people seriously and do not tell them that they are 
delusional as this can upset them more. Validate their 
experience while avoiding acknowledging that it is real (if 
you are certain that it is not)
 » Help people to recognise the ways in which paranoia and 
anxiety are associated with patterns of drug use and with 
harms such as violence or arrest
 » Do not sit behind a desk, take notes or have the client 
face doors or windows
 » Apply cool compresses to the neck, underarms, backs of 
the knees and forehead to help lower body temperature
 » Provide plenty of hydrating fluids (nothing caffeinated or 
sugary)
 » If available, small doses of benzodiazepines can be 
helpful, as can 50–100ml of diphenhydramine (Benadryl/
Dimedrol)
 » When a person is not high, discuss strategies to reduce 
the occurrence of anxiety, paranoia and psychosis, 
including diet, hydration, sleep, breaks, CBT referral, 
moderation of dose, routes of administration, and setting
 » People who are acutely psychotic or aggressive, 
appear to be a danger to themselves or others, or are 
experiencing symptoms of acute toxicity need medical 
attention. For psychological symptoms this includes 
benzodiazepines and, in acute cases, anti-psychotics. If 
vital signs are significantly elevated, an intravenous line, 
cardiac monitoring and emergency care may be needed. 
If appropriate, it is important to check for breathing and 
use rescue breathing if needed
 » Harm reduction providers should not risk their own safety 
if a situation appears to be dangerous
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 » Sexual risk
 » HIV and sexually 
transmitted 
infections (STIs)
 » Provide free access to condoms, lubricant and 
information about STIs and HIV
 » Emphasise the special importance of using plenty of 
lubricant during long, dry or rough sex
 » Provide low-threshold access to HIV and STI testing 
and treatment, as well as contraception and pregnancy 
testing and counselling
 » Understand and acknowledge the role that 
amphetamines play in the sexual lives of users. Rather 
than perceiving amphetamines as the sole source of 
risk, understand that many people use them to facilitate 
sexual activity
 » Discuss pleasure and functionality along with risk to allow 
for more sophisticated strategies of risk reduction
 » Develop a sexual harm reduction plan in advance, 
discussing realistic ways to reduce sex-related harms in 
the context of people’s lives
 » Talk not only about HIV and STIs, but also about sexual 
and physical violence, transactional and commercial sex, 
abusive relationships, housing and other issues intimately 
related to sexual risk behaviours. Addressing the context 
of sexual risk and developing a plan to make behaviours 
less dangerous, possibly through the use of CBT and 
motivational interviewing if of interest to the user, can 
be a successful way to reduce risk in people using 
amphetamines 




 » Dependence, 
excessive weight 
loss, other harms 
associated with 
use
 » Recognise that some people, particularly women, use 
amphetamines to lose or control weight and fear gaining 
weight if they stop using
 » Discuss this fear and help people to develop a plan 
to prevent or manage weight gain, while exploring the 
issues underlying poor body image
 » Use of 
amphetamines 
for work or 
study




 » Remind people that while amphetamines can initially 
help to sustain attention and endurance for long periods 
of time, heavy use eventually makes it very difficult to 
complete a task, focus, or behave appropriately in work 
or study settings
 » Organise separate support groups to respond 
more accurately to the needs of people who use 
amphetamines for different reasons. Truck drivers who 
use methamphetamine while working, for example, are 
likely to have very different concerns than teenagers 




There are presently no approved pharmacological 
treatments available for amphetamine 
use.(57) However, a study undertaken in Australia 
among predominantly intravenous users of 
methamphetamine (n=42, sample size 49) 
found that those receiving a once-daily dose of 
sustained release dexamphetamine (a central 
nervous system stimulant often used to treat 
ADHD and narcolepsy) remained in treatment 
for an average of 86.3 days compared to 
a placebo group, and showed a significant 
decrease in methamphetamine use.(53) In 
short, pharmacotherapy for dependence on 
amphetamines is still in trial phases, with present 
results being inconclusive for drugs such as 
dextroamphetamine,(58) modafinil, buproprion 
and methylphenidate.(59)
In terms of treatment utilisation, one study found 
that drug counselling followed by Narcotics 
Anonymous were the most popular forms, with 
therapeutic community treatments last on the 
list of methamphetamine-dependent people. 
However 35% of people in the study stated they 
had never felt the need to access drug treatment 
services, highlighting the lack of understanding 
regarding treatment by dependent users.(60)
On the whole, behavioural/cognitive interventions 
are the preferred method, with evidence 
supporting their effectiveness(54) and guidelines 
developed in both Australia, the United States(38) 
and the UK.(61) One model that has demonstrated 
success is the Matrix Model, integrating CBT, 
family education, social support and individual 
counselling in a non-confrontational, non-
judgemental style reinforced by peers.(55) While 
some believe that the long-term psychological 
effects of heavy amphetamine use mean that 
people require long-term treatment,(62) others 
have found significant increases in abstinence 
following a session of motivational interviewing 
and behavioural therapy lasting only two to 
four hours.(56) Web-based interventions are 
also being explored using CBT and motivation 
enhancement. However, results indicated 
that this technique did not reduce the use of 
amphetamines.(63)
16 A Global Review of the Harm Reduction Response to Amphetamines: A 2015 Update
Next steps for reducing harms related to 
amphetamine use
The first priority for the international harm 
reduction community should be to support 
the development, evaluation and expansion 
of harm reduction interventions specific to 
amphetamines. Although the evidence for 
interventions is not yet as substantial as that 
for harm reduction interventions among opiate 
users, and pharmacological interventions are 
still at the stages of clinical trial, research on 
these interventions should be prioritised. It 
is important to expand the range of services 
available to people who use amphetamines and 
to work to reduce the spread of HIV and other 
harms among this group.
Harm reduction providers in many countries 
have expressed their need for training on work 
with people who use amphetamines, and 
efforts should be made to make such trainings 
available as soon as possible. The experience 
and knowledge of service providers in countries 
such as the United States or Australia can be 
used to develop expertise in regions such as 
Eastern Europe and Southeast Asia, or in South 
Africa.
Treatment for people who use amphetamines 
also needs to be demystified. There is a 
growing body of research, noted within this 
report, on treatment modalities, and some 
guidelines already exist. Interventions specific 
to amphetamines should be implemented 
and evaluated, and international guidelines 
for treatment developed and promoted: for 
example, adapted outreach of NSPs to reach 
people who use stimulants,(15) together with 
tailored NSP programmes that address both 
sexual risk and injection-related harms specific 
to people who use amphetamines.(57)
Service providers, researchers and policymakers 
also need to consider the negative role of drug 
laws and policies in creating or exacerbating 
harms related to amphetamines. On a macro 
level, it is clear that efforts to suppress one drug 
often lead only to the ‘substitution’ of another that 
is more easily or cheaply available. For example, 
efforts to suppress opium production in Asia led 
to a boom in production of amphetamines.(64) 
Vigorous and even violent prohibition efforts 
succeed only in replacing one drug with another 
that is equally or more harmful. This experience 
is one example among many for the need to re-
examine national and global drug policy.
Prohibition can push production, trafficking and 
use towards more potent, easily concealable 
and transportable forms of drugs.(64) More 
potent forms and more direct methods of 
administration (e.g. injecting crystal meth 
instead of taking amphetamine pills) are more 
likely to cause dependence and other harms, 
including HIV infection. Moreover, punitive 
policies and law enforcement practices can 
push people who use drugs to use quickly and 
wherever they can (e.g. in an alley), inhibiting 
their ability to practice harm reduction.(65) The 
widespread criminalisation of possession for 
personal use in most countries also puts people 
who use amphetamines at risk of coming into 
conflict with the law, and the numerous health, 
economic and social harms that arise as a result. 
Policymakers and advocates need to consider 
the consequences of criminalisation and explore 
other methods of reducing the harms related 
to amphetamine use, such as targeted harm 
reduction services, the provision of evidence-
based education and voluntary treatment 
services, and the decriminalisation of possession 
for personal use.(25) Further research on the 
relationship between drug laws and policies, 
drug use patterns and associated harms would 
be useful in supporting more effective public 
health-oriented drug policies. There is also an 
urgent need for epidemiological studies on 
amphetamine injecting to get the measure of 
methamphetamine use, particularly in countries 
like Iran, where the harm reduction needs of 
17
people who use amphetamines are simply 
not being met,(66) and to establish appropriate 
responses to a growing trend in injecting and 
non-injecting amphetamine use. 
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